Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 12/20 | 0.59 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.50 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.38 |
| ▸ | FEN1 | P39748 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.38 |
| ▸ | CDK1 | P06493 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.34 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18181673 | 0.81 | PTK2 (0.40) | PTK2ALKALOX5APFEN1CDK1 | |
| SCHEMBL18181617 | 0.81 | ALK (0.52) | PTK2ALKALOX5APFEN1CDK1 | |
| SCHEMBL18181705 | 0.80 | PTK2 (0.56) | PTK2ALOX5APFEN1SYK | |
| SCHEMBL1682806 | 0.80 | PTK2 (0.62) | PTK2 | |
| SCHEMBL19920460 | 0.78 | PTK2 (0.39) | PTK2ALKSYK | |
| SCHEMBL18410154 | 0.76 | PTK2 (0.66) | PTK2ALKJAK2 | |
| SCHEMBL1674327 | 0.72 | PTK2 (0.44) | PTK2SYK | |
| SCHEMBL18181699 | 0.72 | SYK (0.41) | PTK2SYK | |
| SCHEMBL1682867 | 0.69 | TRPA1 (0.41) | SYK | |
| SCHEMBL1682791 | 0.69 | PTK2 (0.78) | PTK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10494378-B2 | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2019-12-03 | — | — | US | disclosed |
| EP-3354653-B1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO LTD (CN) | 2019-09-04 | — | — | EP | disclosed |
| US-20190177332-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2019-06-13 | — | — | US | disclosed |
| US-10259816-B2 | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2019-04-16 | — | — | US | disclosed |
| EP-3354653-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | Guangzhou Maxinovel Pharmaceuticals Co. Ltd. (CN) | 2018-08-01 | — | — | EP | disclosed |
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-07-26 | — | — | US | disclosed |
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | GUANGZHOU MAXINOVEL PHARMACEUTICALS CO., LTD. (CN) | 2018-05-10 | — | — | US | disclosed |
| EP-3287463-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. (CN) | 2018-02-28 | — | — | EP | disclosed |
| WO-2017012559-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | 广州再极医药科技有限公司 | 2017-01-26 | — | — | WO | disclosed |
| WO-2016169504-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | 广州再极医药科技有限公司 | 2016-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208604-A1 | FUSED RING PYRIMIDINE COMPOUND, INTERMEDIATE, AND PREPARATION METHOD, COMPOSITION AND USE THEREOF | FLT3, FGFR1, FGFR3 | PTK2 198/4885ALK 39/4885ALOX5AP 2686/4885 |
| US-10494378-B2 | Fused ring pyrimidine compound, intermediate, and preparation method, composition and use thereof | FLT3, FGFR1, FGFR3 | PTK2 198/4885ALK 39/4885ALOX5AP 2686/4885 |
| US-20190177332-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | WEE1, PDK1, WEE2 | PTK2 621/4885ALK 645/4885ALOX5AP 3165/4885 |
| US-20180127420-A1 | CONDENSED-RING PYRIMIDYLAMINO DERIVATIVE, PREPARATION METHOD THEREFOR, AND INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS THEREOF | PDK1, WEE1, DCK | PTK2 712/4885ALK 770/4885ALOX5AP 3148/4885 |
| US-10259816-B2 | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof | WEE1, PDK1, WEE2 | PTK2 621/4885ALK 645/4885ALOX5AP 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.